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Abstract 
Introduction: The current metastatic category (M) of nasopharyngeal carcinoma (NPC) is a “catch‑all” classification, 
covering a heterogeneous group of tumors ranging from potentially curable to incurable. The aim of this study was 
to design an M categorization system that could be applied in planning the treatment of NPC with synchronous 
metastasis.
Methods: A total of 505 NPC patients diagnosed with synchronous metastasis at Sun Yat‑sen University Cancer 
Center between 2000 and 2009 were involved. The associations of clinical variables, metastatic features, and a pro‑
posed M categorization system with overall survival (OS) were determined by using Cox regression model.
Results: Multivariate analysis showed that Union for International Cancer Control (UICC) N category (N1–3/N0), 
number of metastatic lesions (multiple/single), liver involvement (yes/no), radiotherapy to primary tumor (yes/no), 
and cycles of chemotherapy (>4/≤4) were independent prognostic factors for OS. We defined the following subcat‑
egories based on liver involvement and the number of metastatic lesions: M1a, single lesion confined to an isolated 
organ or location except the liver; M1b, single lesion in the liver and/or multiple lesions in any organs or locations 
except the liver; and M1c, multiple lesions in the liver. Of the 505 cases, 74 (14.7%) were classified as M1a, 296 (58.6%) 
as M1b, 134 (26.5%) as M1c, and 1 was not specified. The three M1 subcategories showed significant difference in OS 
[M1b vs. M1a, hazard ratio (HR) = 1.69, 95% confidence interval (CI) = 1.16–2.48, P = 0.007; M1c vs. M1a, HR = 2.64, 
95% CI = 1.75–3.98, P < 0.001].
Conclusions: We developed an M categorization system based on the independent factors related to the prognosis 
of patients with metastatic NPC. This system may be helpful to further optimize individualized care for NPC patients.
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Background
The tumor-node-metastasis (TNM) staging system, 
which describes the anatomic extent of cancer, has been 
widely used to aid clinicians and investigators in planning 
treatment, assessing prognosis, and facilitating commu-
nication [1, 2]. Recent years, great progress in diagnos-
tic imaging and radiation techniques for nasopharyngeal 
carcinoma (NPC) has been developed, and a series of 
modifications have been introduced to the TNM stag-
ing system that focuses on the primary tumor (T) and 
local node (N) descriptors [3–7]. By contrast, the current 
metastasis (M) category is still a “catch-all” classification, 
covering a heterogeneous group of NPCs whose outlooks 
range from potentially curable to incurable [8–11].
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There is emerging evidence that the anatomic extent 
of metastasis closely associates with the prognosis of 
patients with metastatic NPC. Liver metastasis seems 
to be an independent negative prognostic factor versus 
bone or lung metastasis, whereas lung metastasis alone 
appeared to be a relatively favorable prognostic fac-
tor [12–14]. Single metastatic lesion in isolated location 
(organ or site) was reported to associate with prolonged 
survival versus multiple metastatic lesions in isolated or 
multiple locations [14–16]. Moreover, a growing body 
of evidence showed that long-term survival could be 
achieved for selective NPC patients with limited meta-
static lesions by a combination of systemic and local 
therapies [17, 18]. These findings suggest that further 
subdivision of the M category for metastatic NPC may be 
necessary to aid clinicians in assessing the prognosis and 
planning the treatment.
Due to the rarity of synchronous metastatic NPC 
patients, most published studies included both patients 
with synchronous and those with metachronous metas-
tasis, or focused only on the patients with metachronous 
metastatic NPC in their analysis. Only one study specifi-
cally evaluated the prognostic values of metastatic fea-
tures in patients with synchronous metastatic NPC and 
identified no significant findings in multivariate analy-
sis, which may partly result from sample size limitations 
[14]. Because NPC patients with synchronous metastasis 
underwent different treatment regimens and had differ-
ent survival rates versus those with metachronous metas-
tasis [12, 19], a detailed analysis of the data of metastatic 
NPC based on a large cohort of patients with synchro-
nous metastasis is warranted.
In this study, we set out to obtain a detailed analysis 
of data related to synchronous metastatic NPC and to 
design an M categorization system that is simple and use-
ful for the best individualized care for these patients. In 
addition, the implication of this system in the manage-
ment of primary NPC was also assessed.
Patients and methods
Patient selection
The medical records of 1,647 NPC patients with distant 
metastasis treated at the Sun Yat-sen University Cancer 
Center (SYSUCC) between January 2000 and Decem-
ber 2009 were reviewed. The inclusion criteria were as 
follows: (1) histologically confirmed NPC with distant 
metastasis at initial diagnosis and (2) presence of pre-
treatment evaluation including complete history, physi-
cal examination, hematology and biochemistry profiles, 
computed tomography (CT) or magnetic resonance 
imaging (MRI) scans of the head and neck regions, radio-
graphs/CT scans of the chest, sonography/CT scans of 
the abdomen, and whole-body bone scan. The exclusion 
criteria are any of the following: (1) refusal of treatment 
and (2) presence of other malignancies. The Hospital Eth-
ics Committee in SYSUCC approved this study.
Variables and staging workup
A multidisciplinary team consisting of radiation oncolo-
gists, radiologists, and oncologists assembled to review 
the medical charts and imaging data of the metastatic 
NPC patients, with a special focus on the anatomic extent 
of metastasis at the initial diagnosis. The metastatic fea-
tures assessed included the number of metastatic loca-
tions (isolated vs. multiple), the involvement of specific 
metastatic locations, and the number of metastases in 
each metastatic location (single vs. multiple). A new sys-
tem of M category was hereafter proposed, with the vari-
ables described above taken into account.
The T and N categories of the primary NPC were 
staged according to the 7th edition of International 
Union against Cancer (UICC) staging system. Additional 
variables assessed included patient characteristics [sex, 
age, Karnofsky performance score (KPS), and body mass 
index (BMI)] and treatment (cycles of chemotherapy and 
radiotherapy for primary tumor).
Treatment and follow‑up
All patients received palliative chemotherapy as a sys-
temic treatment after admission. The first-line regimen 
was nearly exclusively platinum-based, with cisplatin 
in combination with one or two of the following drugs: 
5-fluorouracil, paclitaxel, gemcitabine, and bleomycin for 
4–6 cycles. Treatment was discontinued by request of the 
patients or for intolerable drug toxicity; the median num-
ber of cycles was 4 (range 1–27). Local therapies such as 
surgery, radiotherapy, interventional embolization, and 
radiofrequency ablation served as options for those who 
still had metastatic lesions after chemotherapy.
Follow‑up and end point
Patients were followed up and evaluated for their 
response to therapy every two cycles during systemic 
chemotherapy and then every 3  months until death. 
The median follow-up period was 20  months (range 
1–120  months). Survival status was verified on August 
31, 2014 by direct telecommunication with the patient 
or their family and by checking the clinic attendance 
records. The primary outcome was overall survival (OS), 
which was defined as the time from diagnosis of distant 
metastasis to death by any causes or the last follow-up.
Statistical analysis
Wilcoxon rank sum and Chi square tests were used 
to compare ordinal and categorical variables between 
three M1 subcategories, respectively. The Kaplan–Meier 
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method was used to estimate the OS, and the estimated 
survival curves for different groups were compared by 
using the log-rank test. All of the covariates that were 
significantly associated with OS were introduced into the 
backward Cox regression model to determine the inde-
pendent prognostic factors. Stratified analysis by the 
proposed M1 subcategories in a multiple-adjusted Cox 
model was further conducted to investigate the associa-
tion between primary radiotherapy and prognosis, with 
covariates including age, UICC N category, and cycles of 
chemotherapy. A two-tailed P value <0.05 was consid-
ered significant. Statistical analysis was performed using 
SPSS 20.0 software (IBM SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 505 NPC patients were involved in this study. 
The baseline characteristics of patients are shown in 
Table 1. The median age was 48 years (range 18–78 years). 
Among the patients, 427 (84.6%) were males, and 78 
(15.4%) were females; 468 (92.7%) had undifferentiated 
non-keratinizing carcinoma, 29 (5.7%) had differentiated 
non-keratinizing carcinoma, and 8 (1.6%) had keratiniz-
ing squamous cell carcinoma; 306 (60.6%) had isolated 
metastasis, and 199 (39.4%) had widespread metastasis. 
The most frequently involved locations for metastases 
were the bones (65.9%), the liver (30.7%), distant lymph 
nodes (28.5%), and the lungs (26.9%); isolated organ 
metastasis was common among the bone (65.9%), the 
lung (41.2%), and the liver (36.1%); and the metastasis 
was rare in distant lymph nodes (6.9%). Multiple lesions 
were detected more frequently than single lesions for all 
the involved organs or locations (Table 2).
M category subdivision and survival
Overall, 312 patients (61.8%) died before the last fol-
low-up. The median OS time was 24.9  months (range 
1–120 months), and the 1-, 3-, and 5-year OS rates were 
80.0%, 34.9%, and 27.0%, respectively, for the whole pop-
ulation (Figure 1a).
The metastatic locations, number of metastatic loca-
tions, and number of metastatic lesions were analyzed 
separately to identify the optimal grouping strategy 
(Table  3). Univariate analysis showed that the involve-
ment of the liver (P  <  0.001) and multiple lesions 
(P  <  0.001) were significantly associated with an unfa-
vorable OS among patients with synchronous metastasis 
(Figure 1b, c). Other factors that significantly associated 
with OS included age, UICC N category, KPS, radiother-
apy to primary tumor, and cycles of chemotherapy.
Multivariate analysis using a backward method and 
including all of the significant prognostic factors men-
tioned above indicated that UICC N category (N1–3/
N0, P = 0.031), number of metastatic lesions (multiple/
single, P = 0.005), liver involvement (yes/no, P < 0.001), 
radiotherapy to primary tumor (yes/no, P  <  0.001), and 
cycles of chemotherapy (>4/≤4, P  <  0.001) were inde-
pendent prognostic factors for patients with synchronous 
metastatic NPC (Table  4). Based on the two independ-
ent prognostic factors, liver involvement and number 
of metastatic lesions, we further subdivided the entire 
cohort of NPC into three M1 subcategories: M1a, single 
lesion confined to an isolated organ or location (the liver 
excluded); M1b, single lesion in the liver and/or multiple 
Table 1 Baseline characteristics of  505 nasopharyngeal 
carcinoma (NPC) patients with synchronous metastasis
All values are presented as numbers of patients followed by percentages in the 
parentheses.
 UICC International Union Against Cancer, KPS Karnofsky performance score and 
BMI body mass index.
a One of the 505 patients with an unspecified metastatic disease cannot be 
classified to any of the three M1 subcategories.
b Fisher’s exact test was used; P < 0.05 was considered significant.
Character‑
istic
Entire group M1 subcategorya P value
M1a M1b M1c
Total 505 74 296 134
Age (years) 0.426
 <48 259 (51.3) 43 (58.1) 149 (50.3) 66 (49.3)
 ≥48 246 (48.7) 31 (41.9) 147 (49.7) 68 (50.7)
Sex 0.212
 Male 427 (84.6) 58 (78.4) 256 (86.5) 112 (83.6)
 Female 78 (15.4) 16 (21.6) 40 (13.5) 22 (16.4)
UICC T category 0.756
 T1 25 (5.0) 3 (4.1) 13 (4.4) 8 (6.0)
 T2 88 (17.4) 14 (18.9) 47 (15.9) 27 (20.1)
 T3 227 (45.0) 29 (39.2) 139 (47.0) 59 (44.0)
 T4 165 (32.7) 28 (37.8) 97 (32.8) 40 (29.9)
UICC N category 0.143
 N0 28 (5.5) 7 (9.5) 18 (6.1) 3 (2.2)
 N1 160 (31.7) 25 (33.8) 90 (30.4) 44 (32.8)
 N2 227 (45.0) 35 (47.3) 128 (43.2) 64 (47.8)
 N3 90 (17.8) 7 (9.5) 60 (20.3) 23 (17.2)
KPS 0.201b
 ≥80 476 (94.3) 73 (98.6) 276 (93.2) 126 (94.0)
 <80 29 (5.7) 1 (1.4) 20 (6.8) 8 (6.0)
BMI 0.699
 ≥18.5 430 (85.1) 65 (87.8) 249 (84.1) 115 (85.8)
 <18.5 75 (14.9) 9 (12.2) 47 (15.9) 19 (14.2)
Radiotherapy to primary tumor <0.001
 No 267 (52.9) 22 (29.7) 147 (49.7) 98 (73.1)
 Yes 238 (47.1) 52 (70.3) 149 (50.3) 36 (26.9)
Cycles of chemotherapy 0.864
 ≤ 4 273 (54.1) 42 (56.8) 159 (53.7) 71 (53.0)
 >4 232 (45.9) 32 (43.2) 137 (46.3) 63 (47.0)
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lesions in any organs or locations except for the liver; and 
M1c, multiple lesions in the liver. Of all the patients, 74 
(14.7%) were in the M1a subcategory, 296 (58.6%) were 
in M1b, and 134 (26.5%) were in M1c, with 1 patient 
not specified. The median OS time for M1a, M1b, and 
M1c subcategories were 46.0, 25.1, and 18.3  months, 
respectively, and the 3-year OS rates were 62.1%, 36.1%, 
17.9%, respectively (Figure 1d). Multivariate analysis sug-
gested that different M1 subcategories showed signifi-
cant difference regarding OS [M1b vs. M1a: hazard ratio 
(HR) =  1.69, 95% confidence interval (CI) =  1.16–2.48, 
P = 0.007; M1c vs. M1a: HR = 2.64, 95% CI = 1.75–3.98, 
P < 0.001] (Table 5).
Radiotherapy for primary NPC and M1 subcategories
Of the 505 patients, 238 (47.1%) received radiotherapy 
for primary NPC, with a total external radiation doses 
ranged from 60 to 78 Gy (median, 72 Gy). A significant 
difference in the distribution of radiotherapy to primary 
tumors was observed between three M1 subcategories. 
Therefore, a further stratified analysis was conducted to 
determine the impact of primary radiotherapy on OS. 
Multiple-adjusted model including age, UICC N category, 
cycles of chemotherapy, and radiotherapy to primary 
tumor indicated that radiotherapy to the primary tumor 
was associated with an improved OS among patients with 
M1b (HR =  0.69, 95% CI =  0.51–0.94, P =  0.017) and 
M1c (HR = 0.43, 95% CI = 0.25–0.74, P = 0.002) tumors. 
In the M1a subcategory, such association was not found 
significant (HR = 0.86, 95% CI = 0.38–1.94, P = 0.716).
Discussion
Our study provided several notable findings: (1) among 
505 NPC patients with synchronous metastasis, the most 
frequently involved organs or sites at diagnosis were the 
bones (65.9%), the liver (30.7%), distant lymph nodes 
(28.5%), and the lungs (26.9%), respectively; (2) UICC N 
category, number of metastatic lesions, liver involvement, 
cycles of chemotherapy, and radiotherapy to primary 
tumors were independently associated with the OS of 
patients with synchronous metastatic NPC; and (3) based 
on liver involvement and number of metastatic lesions, 
we proposed a new M categorization system to further 
subdivide the population into three M1 subcategories, 
which showed a high degree of difference regarding OS 
and have important implications in the management of 
the metastatic disease.
There has been only one report that has specifically 
evaluated the data related to synchronous metastatic 
NPC. Pan et al. [14] retrospectively analyzed the data of 
376 NPC patients with synchronous metastasis, and the 
results in univariate analysis suggested that both liver 
involvement and the presence of multiple lesions were 
unfavorable factors for OS. However, these two factors 
failed to reach significance in multivariate analysis, which 
may possibly be explained by the relatively small sample 
size and the heterogeneity of the involved population, 
Table 2 Location of  metastases and  characteristics within   
the entire cohort of NPC patients
a The percentages of patients with respect to the total of patients with 
metastasis at the corresponding locations.
b The percentage of patients with respect to the total of patients with 
synchronous metastatic NPC.








 Isolated bone metastasis 184 (65.9)
 Total bone metastases 333 (100.0) 65.9
 Number of lesions
  Single metastasis 74 (22.2)
  Multiple metastases 239 (71.8)
  Not specified 20 (6.0)
Lung
 Isolated lung metastasis 56 (41.2)
 Total lung metastases 136 (100.0) 26.9
 Number of lesions
  Single metastasis 42 (30.9)
  Multiple metastases 89 (65.4)
  Not specified 5 (3.7)
Liver
 Isolated liver metastasis 56 (36.1)
 Total liver metastases 155 (100.0) 30.7
 Number of lesions
  Single metastasis 43 (27.7)
  Multiple metastases 102 (65.8)
  Not specified 10 (6.5)
Distant lymph nodes
 Isolated lymph node 
metastases
10 (6.9)
 Total lymph node  
metastases
144 (100.0) 28.5
 Number of lesions
  Single metastasis 15 (10.4)
  Multiple metastases 112 (77.8)
  Not specified 17 (11.8)
Othersc
 Isolated metastasis 0 (0.0)
 Total number of other 
metastases
12 (100.0) 2.4
 Number of lesions
  Single metastasis 4 (33.3)
  Multiple metastases 2 (16.7)
  Not specified 6 (50)
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with the admission time ranging from 1995 to 2007 [14]. 
Therefore, in this study, we conducted a detailed analysis 
based on a large cohort of NPC patients with synchro-
nous metastases admitted to our center between 2000 
and 2009.
The current study introduced the clinical course of syn-
chronous metastasis in a large cohort of NPC patients 
treated in the contemporary era. The OS time after 
metastasis ranged from 1 to 120 months, indicating that 
long-term survival is possible in certain proportions of 
patients with metastases. The median OS time in our 
study was 24.9 months, which was close to the estimated 
25  months reported by Lin et al. [20] and 22  months 
reported by Li et al. [16].
Liver involvement was reported to associate with an 
unfavorable prognosis [21, 22], and lung metastasis alone 
was a favorable prognostic factor among patients with 
metachronous metastatic NPC [13]. By contrast, few 
studies addressed the issue of the prognostic values of 
metastatic locations among patients with synchronous 
metastatic NPC. In our study, a significant difference in 
OS time was found between patients with metastatic NPC 
with and without liver involvement (21.7 vs. 41.1 months, 
P  <  0.001), whereas no significant difference was found 
between patients with lung metastasis alone and those 
with bone metastasis alone or distant lymph nodal metas-
tasis alone. As liver metastasis has been conventionally 
regarded as an indicator of poor prognosis among NPC 
patients, the treatment has largely been palliative [8, 23]. 
In recent years, several studies showed that CT-guided 
radiofrequency ablation (RFA) can be performed with a 
high degree of technical effectiveness and offer the prom-
ise of prolonged survival time in selected NPC patients 
with liver metastases [17, 18]. However, these results must 
be interpreted with caution and future prospective studies 
with a large cohort are needed to validate these findings.
Figure 1 Kaplan–Meier curves of overall survival (OS) in patients with nasopharyngeal carcinoma (NPC). a the entire cohort of NPC patient; b the 
liver metastasis and extra‑liver metastasis groups; c,the groups with single or multiple metastatic lesions; d the groups in different M1 subcategories 
as proposed.
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The association between the number of metastatic 
lesions (single/multiple) and OS has been extensively 
studied and demonstrated to be significant in NPC 
patients with synchronous and metachronous metasta-
ses by a series of studies [14, 15], whereas its prognostic 
value as compared with the number of metastatic loca-
tions remains unknown. It is intriguing that in our study, 
both the number of metastatic lesions (single/multiple) 
and the number of metastatic locations (isolated/mul-
tiple) were significant associated with OS in univariate 
analysis. A multivariate analysis that included all of the 
significant covariates suggested that the number of meta-
static lesions, but not the number of metastatic locations, 
was an independent prognostic factor for OS. These 
results indicated that patients with single metastatic 
lesion need special attention. As there is enormous evi-
dence that NPC patients with single metastatic lesion in 
isolated organ, such as the lung [17, 24], the liver [25], 
and the bone [26], can benefit from combined local and 
systemic therapies [27], an accurate imaging diagnosis for 
Table 3 Overall survival (OS) according to the locations, number of locations, and number of lesions in each location
LN lymph node.
a The total number of patients does not coincide exactly with the corresponding number in Table 2 because the number of lesions for some patients is not specified.
b These include isolated metastasis in the bones, the lungs, the liver, and distant lymph node.
Category and variable Number of patientsa Median OS (months) 3‑year OS rate (%) P value
Isolated metastasis versus multiple metastases
 Number of metastatic locations 0.001
  Multiple locations 199 22.4 24.0
  Isolated location 306 27.4 41.6
 Number of metastatic lesions in each location <0.001
  Multiple lesions 410 22.8 29.5
  Isolated lesion 95 41.0 57.6
Involved locations
 Bone involvement 0.404
  Yes 333 26.2 35.8
  No 172 23.9 33.5
 Lung involvement 0.559
  Yes 136 25.1 30.3
  No 369 24.6 36.6
 Liver involvement <0.001
  Yes 155 19.7 21.7
  No 350 28.4 41.1
 Distant LN involvement 0.104
  Yes 144 23.2 27.6
  No 361 26.7 37.6
Number of lesions and locations
 Isolated bone metastasis 0.065
  Single lesion 50 44.2 60.7
  Multiple lesions 133 25.0 38.6
 Isolated lung metastasis 0.115
  Single lesion 20 57.0 62.1
  Multiple lesions 36 27.2 30.9
 Isolated liver metastasis 0.473
  Single lesion 21 25.6 43.6
  Multiple lesions 35 17.8 22.4
 Isolated distant LN metastasis –
  Single lesion 4 63.7 75.0
  Multiple lesions 6 21.0 54.5
 Total isolated metastasisb 0.002
  Single lesion 95 41.0 57.6
  Multiple lesions 210 23.3 34.6
Page 7 of 9Shen et al. Chin J Cancer  (2015) 34:40 
NPC patients with limited metastatic lesions will be of 
vital importance in identifying this group of patients and 
providing individualized treatment.
A major challenge we face with the TNM staging sys-
tem is how to modify the M categorization system for 
a more precise prognostic prediction and treatment 
planning. Many studies have reported that the greater the 
tumor load, the worse the prognosis in NPC [28, 29]. We 
have proposed a theoretical formula for the assessment 
of metastatic NPC, Vt = V1 + V2 + V3 +, …, + Vn + Vx, 
where V1, V2, V3, …, and Vn are defined as the tumor vol-
ume of each visible lesion under the current best diagnos-
tic imaging system, and Vx is defined as the total tumor 
volume of invisible lesions [30]. The ideal strategy in the 
management of metastatic NPC is to eliminate all the vis-
ible lesions to achieve complete remission (CR) by com-
bined local and systemic therapies and then to eradicate 
invisible lesions (Vx) by using chemotherapy, immuno-
therapy, or targeted therapy. However, this sophisticated 
system that localizes and targets every visible metastatic 
lesion is difficult to practice due to the restrictions in cur-
rent diagnostic and treatment techniques. Hence, an M 
categorization system with a delicate balance of accu-
racy and practicality should be considered. Practicality 
requires that a new category strategy shall be relevant to 
current clinical practice, be evidence-based, and reflect 
the dominant prognostic factors consistently identified 
in Cox multivariate regression analyses. Based on our 
results and a review of the published literature, we pro-
pose to subdivide the status of synchronous metastasis of 
NPC into three M1 subcategories. The advantage of this 
proposed M categorization system is that it can differ-
entiate patients with drastically different prognoses and 
emphasize a more active way to manage patients with 
single metastatic lesion. This system may also be useful 
in the design of clinical trials and help standardize the 
reported results of any therapeutic interventions.
A major controversy exists concerning the necessity 
of treating the primary NPC with an optimal treat-
ment, especially for patients with distant metastases 
involving the liver or multiple organs or sites [20, 31]. 
Since 2011, concurrent chemoradiotherapy was sug-
gested as a choice for selected patients (patients with 
distant metastases in limited sites or with a small 
tumor burden, or patients with symptoms in the pri-
mary or any nodal site) in the National Comprehen-
sive Cancer Network (NCCN) guidelines. In more 
recent years, Tian et al. [15] retrospectively analyzed 
the prognosis of 85 NPC patients initially presenting 
with liver metastasis and found that radiotherapy for 
the primary tumor could significantly prolong sur-
vival time (no/yes: HR  =  2.87, 95% CI  =  1.61–5.10, 
P < 0.001), and 5 patients achieved long-term disease-
free survival after undergoing radiotherapy for the 
primary lesion. Consistent with their study, our study 
showed that primary radiotherapy was independently 
associated with prolonged OS for patients with M1b 
and M1c NPC. These findings revealed that a consid-
erable proportion of patients with extensive distant 
Table 4 Independent prognostic factors from multivariate 
analysis for OS
UICC International Union Against Cancer, HR hazard ratio, CI confident interval.
Variable HR 95% CI P value
Age (≥48 years/<48 years) 1.24 0.99–1.57 0.059
UICC N stage (N1–3/N0) 1.84 1.06–3.19 0.031
Number of metastatic lesions  
(multiple/single)
1.60 117–2.20 0.005
Liver involvement (yes/no) 1.56 1.23–1.96 <0.001
Cycles of chemotherapy (>4/≤4) 0.63 0.50–0.79 <0.001
Radiotherapy to primary tumor (yes/no) 0.59 0.47–0.75 <0.001
Table 5 Univariate and  multivariate analysis in  assessing 
the impact of  M subcategories for  patients with  synchro-
nous metastatic NPC
KPS Karnofsky performance score; BMI body mass index; Ref reference; Other 
abbreviations as in Table 4.
a One of the 505 patients with an unspecified metastatic disease cannot be 
classified to any of the three subcategories.
Variable HR 95% CI P
Univariate analysis
 Age (≥48 years/<48 years) 1.32 1.05–1.65 0.016
 Sex (female/male) 0.85 0.62–1.17 0.319
 UICC T category (T3–4/T1–2) 0.93 0.79–1.22 0.930
 UICC N category (N1–3/N0) 1.93 1.12–3.31 0.017
 KPS (< 80/≥ 80) 1.66 1.03–2.67 0.036
 BMI (<18.5/≥18.5) 1.23 0.90–1.67 0.189
 Radiotherapy to primary tumor (yes/no) 0.52 0.41–0.65 <0.001
 Cycles of chemotherapy (>4/≤4) 0.71 0.57–0.89 0.003
 M subcategorya <0.001
  M1a Ref
  M1b 1.90 1.30–2.76 0.001
  M1c 3.10 2.08–4.62 <0.001
Multivariate analysis
 Age (≥48 years/<4 years) 1.24 0.99–1.56 0.065
 UICC N category (N1–3/N0) 1.83 1.05–3.17 0.032
 Radiotherapy to primary tumor (yes/no) 0.63 0.49–0.80 <0.001
 Cycles of chemotherapy (>4/≤4) 0.63 0.50–0.79 <0.001
 M subcategorya <0.001
  M1a Ref
  M1b 1.69 1.16–2.48 0.007
  M1c 2.64 1.75–3.98 <0.001
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metastases could benefit from radiotherapy for pri-
mary NPC, and further studies are needed to identify 
the targeted patients.
Our study has several limitations. First, it is a ret-
rospective study and the cohort was obtained from 
a specific, regionally based population that may be 
not representative of the general population of NPC 
patients with synchronous metastases. Second, the 
modes of chemotherapy and radiotherapy applied var-
ied, which might have a confounding effect. Third, the 
serum Epstein-Barr virus (EBV) DNA level has been 
demonstrated to be an important prognostic factor 
among patients with recurrent/metastatic NPC [32]; 
however, we failed to include it in our analysis due 
to the lack of data at diagnosis in our cancer center 
(116 patients, 23.0%). The prognostic value of serum 
EBV DNA level and its association with the anatomi-
cal extent of the metastasis of NPC should be fur-
ther assessed. Finally, the metastases of NPC in most 
patients involved in our study were clinically diag-
nosed, and only a small proportion (44 patients, 8.7%) 
had pathologic confirmation, which could be a poten-
tial source of bias. For these reasons, we must validate 
our findings in a multi-institutional prospective study 
in the future.
Conclusions
We developed an M categorization system based on the 
independent prognostic factors related to the metastasis 
of NPC in patients. Multi-institutional external validation 
of this categorization system is warranted in the future.
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